Status:
UNKNOWN
Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
Lead Sponsor:
Federal Neuro-Psychiatric Hospital, Yaba
Conditions:
Schizophrenia and Disorders With Psychotic Features
Eligibility:
All Genders
Phase:
PHASE1
PHASE2
Brief Summary
Sorghum bicolor is a naturally growing plant which has been of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons.The food and nu...
Detailed Description
Schizophrenia is a major psychiatric disorder with a chronic and debilitating course. It is the archetypal psychotic disorder with a prevalence of about 1% worldwide. The treatment of this psychotic d...
Eligibility Criteria
Inclusion
- Participants will be adults with current diagnosis of schizophrenia (meeting the ICD-10 criteria).
- Adults who are above 18 years of age and gave informed consent
- Currently meet the ICD-10 diagnosis of Schizophrenia and confirmed with MINI- PLUS
- Antipsychotic naive before recruitment into study or defaulted from treatment for at least 6 months 'prior to contact with study
- Not on Jobelyn or Megafit currently or in the past 6months prior to contact with study
Exclusion
- Having another current ICD-l0 diagnosis or a seizure disorder
- Serious or chronic physical illness
- Known severe drug allergies or hypersensitivity to Jobelyn, Megafit or Haloperidol
Key Trial Info
Start Date :
June 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02240173
Start Date
June 1 2017
End Date
December 1 2017
Last Update
February 16 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal Neuro-Psychiatric Hospital Yaba - Lagos
Lagos, Lagos, Nigeria, 101212